Work

Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real-world evidence remains limited. METHODS: A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index mortality data for patients initiating nivolumab monotherapy during 2019-2023. Overall survival (OS), time to treatment discontinuation (TTD), and dispensing-based proxies for potential immune-related adverse events (irAEs) were assessed. RESULTS: Among 1398 patients, median OS was 9.3 months and TTD was 7.8 months. Median OS was longer in males than females (10.0 vs. 7.7 months, p = 0.049), while patients with prior corticosteroid exposure had shorter OS than those without (8.3 vs. 11.5 months; aHR 1.20, 95% CI: 1.06-1.36). Incident corticosteroid and levothyroxine use occurred in 10.3% and 10.9% of patients, respectively. CONCLUSIONS: Real-world outcomes were comparable to clinical trial findings, supporting nivolumab's effectiveness in Australian clinical practice.
Source: Head & Neck
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,760
OpenAlex ID: W7230652205
FWCI:
Cites: 44
Cited by:
Related to: 10